Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer

The FDA approved datopotamab deruxtecan-dlnk as the first TROP2-directed antibody drug conjugate for first-line treatment of unresectable or metastatic triple-negative breast cancer in patients ineligible for PD-1/PD-L1 inhibitor therapy.The agency granted priority review and approved datopotamab deruxtecan (Datroway; AstraZeneca, Daiichi Sankyo) based on results from the phase 3 TROPION-Breast02

venerdì 22 maggio 2026 New tab

May 22, 2026

2 min read

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer

Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer

Other newsrooms on this story

Related reading

New First-Line Option Approved in Triple-Negative Breast Cancer

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate…

AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer…

AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC…

Other newsrooms on this story

Related reading

New First-Line Option Approved in Triple-Negative Breast Cancer

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate…

AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer…

AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC…